A major property of IL-10 is to inhibit cell-mediated immunity by blocking several functions of APCs, including the delivery of accessory signals to CD4 + Th cells of the THO or TH1 type (1) (2) (3) . It is therefore anticipated that I1: 10 might play an important regulatory role in the process of allograft rejection. As cyclosporin A (CsA) is currently used in most immunosuppressive protocols in organ transplantation, we were interested in determining the effects of this drug on IL-10 production in vivo.
Since in vitro studies established that in addition to CD4 + cells, macrophages and B cells also represent potential sources of Ibl0 (4-6), two different stimuli were used to induce I1:10 production in mice: the 145-2Cll anti-mouse CD3 mAb as a polyclonal T cell activator, and bacterial LPS as an activating agent for B cells and macrophages. In both settings, increased serum levels of II:10, as well as IL-10 mRNA accumulation in spleen were observed. These two parameters
Materials and Methods
Mice. 6-8-wk-old BALB/c mice and nude mice were obtained from the Katholieke Universiteit ofLeuven (Leuven, Belgium) and from Olac (Bicester, England), respectively.
Agents Injected In Viw The hamster mAb 145-2Cll directed against the mouse CD3 complex (7) was prepared from culture supernatants of 145-2Cll hybridoma cells by affinity chromatography over a protein A-Sepharose column (Pharmacia, Uppsala, Sweden), as previously described (8) . Control hamster Igs were purified from normal hamster serum by the same procedure. The endotoxin levels of these preparations were <15 pg/ml. CsA and its vehicle for parenteral administration were a kind gift of Sandoz Ltd. (Basel, Switzerland). LPS from Escherichia coli was obtained from Sigma Chemical Co. (St. Louis, MO).
ExperimentalPwtocols. Mice received a single intraperitoneal injection of either 145-2Cll mAb (25 #g) or control hamster Igs (25/~g), or LPS (20/~g). Blood samples were obtained by retroorbital puncture at 1.5, 6, 12, and 24 h after injection for measurement of serum II,-10 levels. In separate experiments, mice were killed 2 h after injection for IL-10 mRNA determination in spleen cells. Reverse PCR for IL-IO mRNA. RNA extraction from mouse 0 spleen cells using the guanidininm thiocyanate method, preparation of eDNA and PCK for IL.10 and hypoxanthine phosphoribosyl transferase (HPRT) were performed by standard procedures (11) . Briefly, 1/zg of total RNA was incubated 10 min at 65~ with 1 #g oligo(dT)15 and was further incubated for 60 min at 37~ with 120 U RNasin (Promega Corp., Madison, WI), 1 mM dNTPs, 200 U Moloney murine leukemia virus (Mo-MuLV) reverse transcriptase, 0.01 mg/ml acetylated BSA, and KT buffer (75 mM KC1, 3 mM MgClz, 10 mM DTT, 50 mM Tris HCI, pH 8.3) in a final volume of 20/~1. PCR was performed using aliquots of the resulting cDNA (equivalent to 50 and 500 ng of total RNA for HPKT and IL-10 assays, respectively). To this was added 0.1 mM dNTPs, 2.5 U Taq DNA polymerase, 1/zg of each sense/antisense primer, and PCR buffer (1.2 mM MgClz, 50 mM KC1, 0.001% gelatine, 10 mM Tris HC1, pH 8.3) in a total volume of 25 #1. Primers used have been published (2, 12) . Reactions were incubated in a DNA thermal cycler (Perkin-Elmer Cetus, Norwalk, CT) for 28 cycles (denaturation: 1 min, 93~ annealing: 2 min, 550C; extension: 3 min, 720C). PCR products were run on a 3% agarose gel and stained with ethidium bromide.
$tatis~aIAnalysis. Statistical comparisons were made using the unpaired Student's t test. In each group, values from all mice were included.
Results

Release of 11.,10 in Serum after Injection of Anti-CD3 mAb or LPS into BALB/c Micg Whereas serum from normal
BALB/c mice did not contain detectable II.-10 as assayed by ELISA (lower limit of detection: 0.5 U/m1), the injection of 25 #g of the anti-CD3 mAb 145-2Cll was followed by the appearance of circulating IL-10 ( Fig. 1, top) . body specificity of the 145-2Cll mAb as it was not observed in mice injected with control hamster Igs (Fig. 1, top) .
The injection of LPS (25 #g) into BALB/c animals was also followed by the systemic release of II.-10 ( Fig. 1, bottom) , although ILl0 serum levels were lower than after injection of the 145-2Cll mAb. Ibl0 was detectable in serum 1.5 h after LPS injection in 8 out of 11 mice (mean _+ SEM: 0.68 _+ 0.09 U/ml), and at 6 h in 7 out of 15 mice (mean _+ SEM: 0.67 +_ 0.9 U/ml). No serum I1.-10 was found at later time points.
CsA Prevents Anti-CD3 mAb-induced Production but Enhances LPS-induced 11,10
Production. The in vivo effects of CsA on the systemic release of IIr were investigated in animals pretreated with two 25-mg/kg i.p. injections of CsA given 18 and 3 h before challenge with anti-CD3 mAb or LPS (Fig.  2) . CsA completely prevented the systemic release of IL-10 induced by anti-CD3 mAb as indicated by the lack of detectable serum Ibl0 at all time points studied. As control, mice were pretreated with CsA vehicle alone before anti-CD3 mAb injection. The 1I.-10 serum levels in these animals were similar to those measured in the absence of pretreatment (mean + SEM at 6 h: 1.69 + 0.46 U/ml). In contrast with its inhibitory effect on anti-CD3 mAb-induced II.-10 production, CsA pretreatment led to a major increase in the II-10 serum levels measured 6 h after LPS challenge (mean + SEM: 8.31 + (Fig. 2) .
We analyzed whether the effects of CsA on Ibl0 release were related to modulation of I1,10 gene expression. No or minimal expression of IL-10 mRNA was found in spleens of untreated mice or of mice injected with CsA alone (Fig.  3) . Anti-CD3 mAb injection led to a marked accumulation of II.-10 mRNA which was almost completely prevented by CsA pretreatment (Fig. 3) . LPS also led to I1,10 gene induction and in this setting CsA pretreatment resulted in a clear increase in IL-10 mtLNA accumulation (Fig. 3) .
LPS but Not A nti-CD3 mA b Induces ILIO Production in Nude
Mice. The role of T cells in II.-10 production induced by anti-CD3 mAb or LPS was investigated by challenging nude mice with these stimuli. Neither unmanipulated nude mice nor nude mice injected with anti-CD3 mAb displayed significant I1,10 gene transcription (Fig. 4) . I1,10 also remained undetectable in their serum at all time points. On the other hand, as in BALB/c mice, LPS injection led to I1,10 mRNA accumulation (Fig. 4) and induced a systemic release of IL-10 (mean _+ SEM at 6 h: 0.63 _+ 0.10 U/ml, n = 5), which was further increased by CsA pretreatment (mean _+ SEM at 6 h: 4.82 + 1.35 U/ml, n -5, p < 0.05 as compared with LPS alone).
Discussion
The first observation of this study is that both anti-CD3 mAb and LPS induce the release of immunoreactive I1,10 in the bloodstream of normal mice. The range of II.-10 serum levels in both settings was quite large, with some samples remaining below the detection limit. Such wide dispersion of cytokine serum levels has been previously observed in similar models (13, 14) . It is likely that the cell types involved in II.-10 production after injection of anti-CD3 mAb or LPS are different. Indeed, experiments in nude mice established that T cells are required for anti-CD3 mAb-induced but not for LPS-induced II,10 production. As previously demonstrated for IL-2, IFN-% and I1,4 mtkNAs (15), we might thus assume that T cells are the major source of II.10 after injection of anti-CD3 mAb. Along this line, it was recently shown that the CD4 + cell population was the cell type in which I1.10 mRNA accumulates after injection of anti-mouse IgD mAb (16) . As far as LPS-induced II.-10 production is concerned, both macrophages and B cells, especially Ly-1 + B cells, might be involved (5, 6) . Whatever its precise cell source, I1,10 might be responsible for some of the immune disturbances observed after injection of anti-CD3 mAb or LPS. First, the long-lasting immunosuppressive effects of anti-CD3 mAbs which have been observed both in experimental and clinical transplantation (17, 18) could be related, at least in part, to the production of I1,10. The immunosuppression observed after LPS injection (19, 20) could also represent a consequence of I1,10 production. Experiments using neutralizing anti-I1,10 mAb or mice made IL-10-deficient by gene targeting should help to define the exact role of IL-10 in the immunosuppression induced by anti-CD3 mAb and LPS.
The main findings reported in this paper concern the differential effects of CsA on the production of IL-10 induced by anti-CD3 mAb or LPS. Although it has been well established that CsA inhibits in vitro and in vivo the transcription of several cytokine genes in mouse T cells including II.-2, IFN-'},, and II,-4 genes (9, 21, 22) , it was recently reported that the drug does not affect the production of Ibl0 by a TH2 clone (23) . The experiments described herein clearly establish that CsA blocks the systemic release of IL-10, as well as II--10 gene expression induced by anti-CD3 mAb in vivo. In contrast, CsA pretreatment in the LPS model resulted in the superinduction of IL-10 gene expression and in a dramatic enhancement in the systemic release of IL-10. Similar gene superinduction by CsA has been previously reported for TGF-/~ in human T cells (24) , for IL-6 in human PBMCs (25) , and for the Ly-6E surface antigen in the T cell lymphoma-derived YAC-1 cell line (26) . Mechanisms proposed to explain CsA-mediated cytokine gene superinduction include the inhibition of the production of nuclear factors binding to negative regulatory sequences of corresponding gene or the lack of inhibition of regulatory proteins that promote cytokine gene expression (24, 26) . Our experiments in nude mice indicate that the enhancement by CsA of LPS-induced IL-10 gene expression and Ibl0 production does not depend on the action of the drug on T cells and could therefore be related to a direct effect on Ibl0-producing cells.
The in vivo effects of CsA on IL-10 production might be relevant to clinical settings where CsA is used to induce immunosuppression, such as in organ transplantation or in autoimmune diseases. Administration of CsA in transplant recipients receiving the OKT3 mAb has been recommended to reduce the antibody response to the mAb. However, by blocking OKT3-induced Ibl0 production, CsA might also inhibit an important pathway of immunosuppression. In patients developing endotoxemia under CsA therapy, the enhanced II~10 production might be beneficial by reducing the release of TNF-ot and IL-1 (27) , but detrimental by accentuating the Th cell defects induced by LPS.
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